The hypoglycemic drugs, sodium-glucose cotransporter-2 (SGLT2) inhibitors, have emerged as formidable drugs demonstrating primary and secondary prevention of HF events in both T2DM and non-diabetes mellitus (DM) patients [8,10]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.